NCT05057546

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate changes in blood vessels around the heart (e.g., aorta and carotid arteries) and in the brain with the loss of female sex hormones (e.g., estrogen) during the menopause transition. The menopause transition is associated with declines in blood vessel function and increased risk for cardiovascular disease and Alzheimer's disease. Increasing evidence supports an early role for declines in blood vessel function and future development of Alzheimer's disease in aging men and women. This study will learn about the effects of changes in female sex hormones, such as estrogen, during the menopause transition on blood vessel around the heart and in the brain in women.

Conditions

• Menopause
• Estrogen Deficiency
• Women
• Aging

Interventions

Type	Name	Description
DRUG	GnRH antagonist	GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)

Timeline

• Start date: 2021-11-22
• Primary completion: 2024-09-18
• Completion: 2025-07-28
• First posted: 2021-09-27
• Last updated: 2025-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study